Drug intelligence / Profile preview

α3nAChR siRNA

Development stage
Unknown
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intrathecal
01

Overview

α3nAChR siRNA is a small interfering RNA (siRNA) designed to specifically silence the expression of the alpha 3 subunit of the nicotinic acetylcholine receptor (α3nAChR), which is encoded by the CHRNA3 gene. In the context of Alzheimer's disease research, this tool is utilized to investigate the regulatory role of α3nAChR in the amyloidogenic pathway. Experimental evidence in human neuroblastoma SH-SY5Y cells indicates that silencing α3nAChR leads to the downregulation of key components involved in amyloid precursor protein (APP) processing, such as ADAM10 (α-secretase), presenilin 1 (PS1), and nicastrin (NCT), as well as effectors in the Notch signaling pathway (Notch1 and Hes1). These findings suggest that α3nAChR may promote the non-amyloidogenic processing of APP and exert a protective effect against β-amyloid (Aβ) production.

Other names
CHRNA3 siRNACHRNA-3 siRNACHRNA 3 siRNAnicotinic acetylcholine receptor alpha 3 subunit siRNA
02

Targets

Innate immune RNA sensorsCHRNA3 (nAChR α3 subunit)

Beyond the preview

Go deeper on α3nAChR siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on α3nAChR siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call